Loading stock data…
IVVD
$1.52+0.12 (+8.57%)
Market ClosedLast close May 1
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Invivyd, Inc. in the Healthcare sector is trading at $1.52. The stock is currently 50% below its 52-week high of $3.07, remaining 7.3% below its 200-day moving average. Technical signals show neutral RSI of 38 and bearish MACD signal, explaining why IVVD maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 38) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.52
Potential Upside
5%
Whystock Fair Value$1.60
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus3 analysts
Mean target$10.00+557.9%
Range$10.00 – $10.00
Fundamentals
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$452.49M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.74
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-21.73%
Volume
Today's trading volume
1.88M
Recent News
Invivyd (IVVD) Announces Favorable Phase 3 Analysis for VYD2311 COVID-19 Treatment
Invivyd Inc. (NASDAQ:IVVD) is one of the best NASDAQ growth stocks to buy and hold forever. On April 9, Invivyd announced significant progress in its REVOLUTION clinical program, specifically regarding VYD2311, a monoclonal antibody candidate for COVID-19 prevention. A pre-specified analysis of the Phase 3 DECLARATION study revealed that accumulated clinical events already provide sufficient […]
Stock Market Today, April 9: Markets Extend Gains as Ceasefire Holds
Today, April 9, 2026, Amazon’s in‑house AI chip push helped power gains as investors weighed fresh inflation risks and oil price volatility.
Invivyd Updates VYD2311 REVOLUTION Trials, Modestly Upsizes Study, Unveils Measles mAb VMS-063
Invivyd (NASDAQ:IVVD) provided updates on its REVOLUTION program for COVID-19 monoclonal antibody candidate VYD2311 and announced the discovery and early development work for a measles monoclonal antibody candidate, VMS-063, during a conference call led by board chairman Marc Elia alongside Chief Sc
Exploring Three High Growth Tech Stocks In The US Market
Over the last 7 days, the United States market has experienced a 1.6% drop, yet it has seen a significant 15% rise over the past year, with earnings expected to grow by 16% annually. In this context of fluctuating market conditions and promising growth forecasts, identifying high-growth tech stocks involves assessing their potential for innovation and scalability within this dynamic landscape.
Invivyd Q4 Earnings Call Highlights
Invivyd (NASDAQ:IVVD) executives used the company’s fourth-quarter 2025 earnings call to outline progress in its COVID-19 monoclonal antibody pipeline, provide an update on commercialization of PEMGARDA, and review recent financial results and liquidity. Leadership update and strategic focus Chairm